S

Spero Therapeutics
D

SPRO

0.81200
USD
-0.02
(-2.64%)
مغلق
حجم التداول
4,273
الربح لكل سهم
-1
العائد الربحي
-
P/E
10
حجم السوق
44,268,750
أصول ذات صلة
    CVX
    CVX
    -1.850
    (-1.16%)
    156.970 USD
    MPC
    MPC
    -4.487
    (-2.83%)
    153.808 USD
    PSX
    PSX
    -2.730
    (-2.08%)
    128.820 USD
    VLO
    VLO
    -4.353
    (-3.13%)
    134.767 USD
    XOM
    XOM
    -1.320
    (-1.18%)
    110.700 USD
    المزيد
الأخبار المقالات

العنوان: Spero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.